File photo of Aurobindo Pharma office. , Photo courtesy: The Hindu
Aurobindo Pharma reported consolidated net profit rose nearly 4% to ₹848 crore in the September quarter from ₹817 crore a year ago, due to higher formulation revenues.
The Hyderabad-headquartered generic drugmaker posted net profit at ₹8,286 crore (₹7,796 crore) on the back of over 6% growth in revenue from operations.
Vice President and MD. Nityananda Reddy said, “Q2 has been another stable quarter for Aurobindo, demonstrating the resilience of our base business and the depth of our product portfolio. We are seeing healthy demand across key markets, with our US and Europe businesses performing in line with expectations.”
Formulations’ share in revenue was up 10.3% year-on-year at ₹7,325 crore (₹6,640 crore), while active pharmaceutical ingredients (API) contribution fell 16.9% to ₹961 crore (₹1,156 crore).
“Given the momentum we have built and all strategic initiatives moving forward as planned, we are confident of meeting our annual guidance and maintaining long-term value creation,” he said.
published – November 05, 2025 11:12 pm IST
